Abstract
Introduction

Smooth muscle contraction in the vasculature is a key determinant of blood pressure and blood flow. A major mechanism of initiation of smooth muscle contraction is phosphorylation of the regulatory myosin light chain (LC20), which is largely determined by the opposing activities of myosin light chain kinase (MLCK) and myosin phosphatase. The myosin phosphatase holoenzyme is a heterotrimer composed of the 38 kD protein phosphatase 1 (PP1) catalytic subunit, a 110-133 kD myosin phosphatase target subunit (MYPT1), also termed myosin binding subunit (MBS), and a 20 kD subunit of unknown function [1]. While initially assumed to be constitutively active, myosin phosphatase is now considered as regulated by various pathways, most of which lead to inhibition of myosin phosphatase by phosphorylation of MYPT1 at threonine-696 and/or threonine-850. The kinases that have been implicated in inhibitory
phosphorylation of MYPT1 are ROCK [2, 3] , ILK [4] and ZIPK [5, 6] . ZIPK is expressed in various smooth muscle tissues such as intestine, vascular tissues and bladder, where it is associated with the regulatory subunit of myosin phosphatase, MYPT1 [5, 6] .
In the process of investigating signalling pathways involved in regulation of smooth muscle myosin phosphatase, the pro-apoptotic protein Par-4 (prostate apoptosis response-4) attracted our interest, since has been shown to interact with ZIPK in non-contractile cells [7, 8] . [9] . Subsequent reports also characterized [10] .
was originally identified as the product of a gene that is up-regulated upon ionomycin-induced apoptosis in prostate cancer cells
chiefly as a proapoptotic protein. Loss of Par-4 function was found to play a role in tumourigenesis, identifying the protein as a tumour suppressor. On the other hand, up-regulation of Par-4 has been linked to neuronal apoptosis in neurodegenerative diseases like amyoloid lateral sklerosis (ALS) and Alzheimer's disease, and in animal models of Parkinson's disease and Huntington's disease
In the setting of apoptosis in non-muscle cells, the Preuss group [11] [12, 13] . Ferret tissues were used in this study because of the increased similarity of ferret proteins and physiological functions to the human relative to rodents [14] [15] [16] .
Material and methods
Tissue and cell preparation
Cell culture and transfection
A7r5 rat aorta cells were cultured in DMEM high glucose (Invitrogen) with 10% FCS, 1% glutamine, 50 units/ml penicillin and 50 g/ml streptomycin. Cells were transiently transfected with a GFP-tagged ZIPK construct [17] performed with the jetPEI transfection reagent (PolyPlus, Illkirch, France) . Transfected cells were subjected to a 24 hrs serum starvation prior to preparation of cell extracts.
Digital imaging
Cells were fixed, stained and analyzed as described previously [13] 
Co-immunoprecipitation and pull-down experiments
Antisense experiments
Morpholino oligonucleotides were purchased from Gene Tools, LLC (Philomath, OR). Par-4 protein expression was suppressed using the antisense morpholino oligonucleotide 5Ј-CGGTAGCCACCGGTCGCCATATTCC-3Ј complementary to the 5Ј part of the ferret Par-4 gene including the initiation codon (underlined). The scrambled morpholino nucleotide 5Ј-CGC-CGTGTCTGATCTTCGTGCATCC-3Ј served as control. Ferret portal vein
strips were chemically loaded with the morpholino oligonucleotides at 50 mol/L performed with a previously described protocol [12] . On the fifth day of organ culture after loading, the muscle strips were quick-frozen following contractility assessment. 
Results
Par-4 and ZIPK are expressed in vascular smooth muscle
After testing for antibody specificity (Fig. 1A) , western blot analysis (Fig. 1B) Fig. 2A, graph) . [7, 22, 23] . By choosing this sequence, the decoy peptide was designed to compete with endogenous Par-4 in binding to ZIPK. Pull-down experiments were performed to test the efficacy of the decoy peptide. As shown in Figure 2C (Fig. 3A) . Although the effect is not large, consistent with the known redundancy of multiple signalling pathways in dVSM [24] , it is highly statistically significant. Furthermore, the effect of the decoy peptide was specific for PGF-2␣ and also for KCl-induced contraction, since it had no effect on phenylephrineinduced contractility (data not shown).
Pre-treatment of cells with the decoy peptide before stimulation with PGF2␣ for 1 min inhibits the targeting of ZIPK to the actin filaments (Fig. 2D). Quantitative analysis shows that the percentage of cells with filamentous ZIPK staining pattern significantly decreases in the decoy peptide treated cells compared to the scrambled peptide treated cells.
The Par-4 decoy peptide and Par-4 knock down interfere with smooth muscle contractility
Our results predict that Par-4 targets ZIPK to the contractile filament bundles and to its substrates MYPT1 and LC20, thus presumably supporting contraction. To prove whether Par-4 indeed modulates contractility, we employed the previously described cell permeant Par-4 decoy peptide (see Fig. 2B) in force transduction experiments. Tissues were pre-treated with either the scrambled control peptide or with the decoy peptide prior to contractility assessment. Loading efficiency was monitored by immunofluorescence analyses of tissue pieces (data not shown). Compared to the control strips, contraction of the tissues treated with the decoy peptide is significantly reduced after 10-min PGF-2␣ stimulation
As a second approach to analyze the contribution of Par-4 in smooth muscle contractility, we used antisense knockdown ofPar-4 with antisense morpholino nucleotides. On day five after morpholino loading in serum-free organ culture, the contractility of the treated tissues was significantly reduced (Fig. 3B) (Fig. 3C, black bars) . To test our hypothesis that Par-4 promotes ZIPK translocation, thereby facilitating ZIPK-mediated phosphorylation of MYPT1 and LC20, we analyzed the phosphorylation of these ZIPK substrates in the morpholino-treated tissues For MYPT1, the threonine-850 phosphorylation site was chosen since its phosphorylation has been connected with detachment of MYPT1 from myosin [25] , which may cause the agonist-induced redistribution of MYPT1 that has been previously observed in this same cell type [13] . Interestingly, a significant reduction of both MYPT1 and LC20 phosphorylation could be demonstrated: At steady-state contraction, MYPT1 phosphorylation at threonine-850 was reduced to 87.07 Ϯ 5.22% in the antisense-treated strips compared to the control strips, and LC20 phosphorylation was reduced to 87.67 Ϯ 4.67% (Fig. 3C, dark grey bars A recent publication has suggested that the Par-4/ZIPK interaction is restricted to rodent cells [26] . However To the best of our knowledge, besides the data presented here, only one other non-apoptotic function for Par-4 has been described so far: the regulation of dopamine signalling in neuronal cells by interaction with the dopamine D2 receptor [39] . Apart from dopamine signalling, Par-4 has been associated with neuronal apoptosis and appears to be involved in the pathology of several neurodegenerative diseases [40] . We 
